Grifols says Canada license suspension has no impact; Grifols stock costs EUR 9.52
Published on 10/03/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 24, 2026, Grifols said Health Canada's decision to suspend its license to collect plasma at the Taylor Avenue facility in Winnipeg had no impact on ongoing operations, according to Reuters. Separately, Grifols stock was EUR 9.52 in weekend trading at Lang & Schwarz at 11:25 a.m. CEST on October 3, 2026, unchanged versus the EUR 9.52 close at Lang & Schwarz on October 2, 2026.
Weekend trading at Lang & Schwarz
The EUR 9.52 price was unchanged from the EUR 9.52 close at Lang & Schwarz on October 2, 2026. The bid was EUR 9.48 and the ask was EUR 9.57 at 11:25 a.m. CEST on October 3, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Grifols stock.
The last Xetra trading day
Lang & Schwarz recorded a EUR 9.52 close for Grifols on October 2, 2026. The weekend price and that reference close were identical.
Canada plasma license update
Reuters reported that Health Canada's suspension concerned Grifols' license to collect plasma at the company's Taylor Avenue facility in Winnipeg. Grifols said the decision had no impact on ongoing operations, according to Reuters.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
